Location: United Kingdom
Through their AI and machine learning tools, Benevolent AI is making drug development faster and more affordable.
Currently, bringing a new medication to market takes years of development and testing, costing billions. With so many diseases lacking effective treatment, the traditional method of drug development has room for improvement. Lowering the cost of new drug development and speeding up the process is a critical part of advancing treatment for many diseases and illnesses. That’s where computational medicine comes in, with start-ups like Deep Genomics and Benevolent AI paving the way.
Benevolent AI has raised almost $300 million in funding since it was founded in 2013. Their AI and machine learning tools can predict potential disease targets and calculate the likely response to different drugs. Using computational models, rather than trial and error, will greatly reduce the likelihood of failures during drug trials. Another benefit of AI is faster, more accurate decision making for precision medicine.
Making drug discovery better will lower the cost of drugs, increase their efficacy, and make drug development for rare diseases more possible financially. The company is currently working on drug development and testing for Covid-19 treatment. Previous work has included combining the expertise of AstraZeneca on a difficult to treat condition called idiopathic pulmonary fibrosis and a more common condition called chronic kidney disease to help use their data to find potential treatment options. Their vision is bold, ‘A world in which no disease goes untreated.’